Variant analysis of the sporozoite surface antigen gene reveals that asymptomatic cattle from wildlife-livestock interface areas in northern Tanzania harbour buffalo-derived T. parva

Buffalo-derived Theileria parva can ‘break through’ the immunity induced by the infection and treatment vaccination method (ITM) in cattle. However, no such ‘breakthroughs’ have been reported in northern Tanzania where there has been long and widespread ITM use in pastoralist cattle, and the Cape buffalo (Syncerus caffer) is also present. We studied the exposure of vaccinated and unvaccinated cattle in northern Tanzania to buffalo-derived T. parva using p67 gene polymorphisms and compared this to its distribution in vaccinated cattle exposed to buffalo-derived T. parva in central Kenya, where vaccine ‘breakthroughs’ have been reported. Additionally, we analysed the CD8+ T cell target antigen Tp2 for positive selection. Our results showed that 10% of the p67 sequences from Tanzanian cattle (n = 39) had a buffalo type p67 (allele 4), an allele that is rare among East African isolates studied so far. The percentage of buffalo-derived p67 alleles observed in Kenyan cattle comprised 19% of the parasites (n = 36), with two different p67 alleles (2 and 3) of presumptive buffalo origin. The Tp2 protein was generally conserved with only three Tp2 variants from Tanzania (n = 33) and five from Kenya (n = 40). Two Tanzanian Tp2 variants and two Kenyan Tp2 variants were identical to variants present in the trivalent Muguga vaccine. Tp2 evolutionary analysis did not show evidence for positive selection within previously mapped epitope coding sites. The p67 data indicates that some ITM-vaccinated cattle are protected against disease induced by a buffalo-derived T. parva challenge in northern Tanzania and suggests that the parasite genotype may represent one factor explaining this. Electronic supplementary material The online version of this article (10.1007/s00436-020-06902-1) contains supplementary material, which is available to authorized users.


Introduction
Theileria parva is a tick-transmitted protozoan tick-borne haemo-pathogen which causes East Coast fever (ECF), a frequently lethal and economically important disease of cattle in Eastern, Central and Southern sub-Saharan Africa (Norval et al. 1991). ECF has been conservatively estimated to be responsible for US$ 300 million of loss annually and kills approximately 1 million cattle per year (Mukhebi et al. 1992). The disease is most severe in exotic taurine cattle in the absence of control but has also been demonstrated, particularly in Tanzania and Kenya, to induce high mortality in zebu calves in resource-poor pastoralist systems (Di Giulio et al. 2009;Thumbi et al. 2013). After nearly a century of acaricide use in the management of tick-borne diseases including ECF, the development of resistance by ticks, environmental contamination and food safety concerns resulting from toxic residues are rendering the approach unsustainable in the medium term (George et al. 2004). Chemotherapy of ECF is usually ineffective in the absence of early diagnosis which is often impractical in field situations (Matovelo et al. 2003).
The ability to grind up whole infected R. appendiculatus vector ticks and cryopreserve T. parva sporozoites that can be inoculated into cattle simultaneously treated with a longacting formulation of oxytetracyline was critical to the development of the infection and treatment method (ITM) of live vaccination (Cunningham et al. 1973;Radley et al. 1975). This approach remains the only practical way of inducing immunity against T. parva in cattle, as there are currently no subunit vaccines that provide protection equal or superior to ITM. Early experiments demonstrated that a panel of three stocks of T. parva provided broader protection against heterologous challenge than any single stock (Cunningham et al. 1974). These cross-protection experiments resulted in the development of the trivalent Muguga cocktail version of ITM which comprises the Muguga, Serengeti-transformed and Kiambu 5 stocks of T. parva (Radley et al. 1975). The logistical and policy constraints related to production and delivery that initially constrained ITM deployment and the technical developments that have increased ITM adoption have been the subject of a recent review .
One aspect of T. parva epidemiology pertinent to ITM efficacy is the presence of a wildlife reservoir population of the parasite in the Cape buffalo (Syncerus caffer). Exposure of cattle to buffalo-derived T. parva results in Corridor disease, a frequently lethal clinical syndrome characterised by low levels of schizonts, the parasite's intra-lymphocytic stage and scanty piroplasm parasitaemia (Irvin and Mwamachi 1983;Jura and Losos 1980). These pathological features are distinct from ECF caused by T. parva that is transmissible between cattle by ticks, which tends to be associated with a high piroplasm parasitaemia. Importantly, studies have shown that ITMvaccinated cattle can be susceptible to challenge with parasites from buffalo. The earliest study of this kind involved keeping ITM-immunised cattle in paddocks together with buffalo (Radley et al. 1979). The conclusion of the research was that T. parva parasites from ticks fed on buffalo could sometimes 'break through' the immunity induced by ITM. While both buffalo and cattle T. parva strains have identical life cycles, evidence suggests that the ECF causing T. parva is better adapted to cattle and is thought to represent a restricted subset of the overall T. parva population (Pelle et al. 2011;Sitt et al. 2019). Two recent attempts to immunise cattle against buffalo-derived T. parva in field trials by grazing ITMimmunised cattle adjacent to buffalo in ranches in central Kenya both resulted in vaccinated animals contracting severe disease Sitt et al. 2015).
No comparable studies have been undertaken to monitor the effects of ITM use in field situations where cattle are exposed to T. parva originating from buffalo in the other East African countries, including Uganda and Tanzania where several wildlife-livestock interface areas also exist. Of the very limited ITM vaccinations that have been performed in cross-bred or taurine cattle in Uganda, none has been in areas where cattle are exposed to field challenge by buffalo-derived parasites (Nsubuga-Mutaka 1999). By contrast, the first successful large-scale deployment of the original trivalent Muguga cocktail version of ITM, without apparent 'breakthrough' infections, has been in Maasai pastoralist systems in northern Tanzania, where there has been long-term co-grazing between cattle and Cape buffalo (Di Giulio et al. 2009). Understanding the reason for absence of breakthrough infections in northern Tanzania will be important for assessing the probability of future success of the cocktail in other wildlifelivestock interface regions.
The explanation advanced for the failure of ITM to induce cross-protection against locally circulating T. parva populations in wildlife-livestock interface areas is that the cocktail contains only a very small proportion of the diversity within the T. parva gene pool in Kenya (Hemmink et al. 2016;Pelle et al. 2011;Sitt et al. 2015). Cape buffalo is known to be infected with multiple T. parva genotypes (Oura et al. 2011) and harbours a much greater diversity of the parasite based on the analysis of genes encoding schizont antigens that are the focus of ongoing recombinant vaccine trials (Pelle et al. 2011). The extent to which the gene pools of buffalo and cattle T. parva populations are separate in Tanzania is not known. In addition, there is as yet no evidence that vaccinated cattle immune to ECF in the Maasai pastoralist systems in northern Tanzania are being challenged by T. parva transmitted by ticks that have fed on buffalo. To address these issues, we have sampled pastoralist cattle from an area in northern Tanzania that is contiguous with the parks, reserves and conservation areas, where there has been long-term co-grazing between the cattle and buffalo.
Transmission of T. parva from buffalo to cattle was sought by examining the major sporozoite surface antigens (p67) alleles that have been shown in recent studies to be presumptive of T. parva originating from buffalo (Nene et al. 1996;Obara et al. 2015;Sibeko et al. 2010;Sitt et al. 2019). Four p67 alleles have been described based on the presence or absence of 129-and 174-bp deletions within the p67 gene central region (Nene et al. 1996;Sibeko et al. 2010). Within East Africa, T. parva parasites that are transmissible between cattle by ticks have been frequently observed to carry the p67 allele type 1 which is relatively conserved and is characterised by a 129 bp deletion in the central region as exemplified by the Muguga strain of T. parva (Nene et al. 1996). By contrast, the T. parva carrying the more heterogeneous p67 allele types 2-4 is known to originate from buffalo and has been shown to be associated with Corridor disease in livestock-wildlife interface areas, where cattle are exposed to infective ticks that have fed on infected African Cape buffalo (Mukolwe et al. 2020;Obara et al. 2015;Sibeko et al. 2010;Sitt et al. 2019). Recently however, a type 1 allele also associated with buffalo T. parva from South Africa but differing from the East Africa cattle type 1 p67 alleles by amino acid changes in the areas flanking the deletion and the epitope regions has been described (Mukolwe et al. 2020). In addition to assessing the level of exposure of Tanzanian pastoralist cattle to buffalo type T. parva based on p67 gene polymorphism, we also determined how similar the p67 alleles at the interface areas in Tanzania were to alleles carried by buffalo-associated T. parva strains in Kenya. Additionally to provide an initial indication of how variable the genes encoding T. parva schizont antigens are in northern Tanzania, we have also studied the molecular evolution of a T. parva candidate subunit vaccine antigen (Tp2) containing epitopes known to be recognised by immune African cattle cytotoxic T lymphocytes (Akoolo et al. 2008). For comparison, we also analysed blood samples from central Kenya obtained from clinically reacting cattle that exhibited the typical signs of Corridor disease in an ITM controlled trial .

Sample collection and processing
The Tanzanian study areas comprised the Monduli and the Simanjiro plains in northern Tanzania (Fig. 1), which are areas of intensified wild-domestic animal interaction due to proximity to game reserves and national parks. These regions are predominantly inhabited by pastoralist Maasai communities who largely depend on livestock for subsistence and represent areas with wide deployment of the ITM vaccine against ECF in Tanzania. Five villages in Simanjiro (Loiborsoit, Terrat, Emboret, Narakawo and Sukuro) were selected based on their proximity to national parks. Consent from local authorities and individual farmers was obtained after explaining the outline and relevance of the study. Certified veterinary personnel collected blood from asymptomatic cattle that included both non-vaccinated (n = 104) and vaccinated (n = 56) cattle that were differentiated on the basis of ear tag numbers that indicated year of vaccination with confirmation by respective farmers. Additionally, buffalos (n = 22) were sampled from the Serengeti National Park with the involvement of Tanzania Wildlife Research Institute (TAWIRI). Blood was collected in 10-ml EDTA vacutainer tubes that were temporarily maintained in ice-cooled boxes while on transit to the laboratory for further processing at the Genome Science laboratory, College of Veterinary Medicine and Biomedical Sciences, Sokoine University of Agriculture.
The archived blood samples from Kenya (n = 100) included in this study were originally collected during an ITM efficacy trial in the Marula area of Kenya . Briefly, T. parva naive cattle were vaccinated using the Muguga cocktail version of ITM and exposed to natural challenge by grazing adjacent to buffalo. DNA from frozen whole blood samples was isolated using NucleoSpin Blood Mini kit for DNA from blood (Macherey-Nagel) according to manufacturer's protocol.
Since buffalos are frequently infected with multiple strains of T. parva, Tp2 and p67 amplicons from buffalo samples were cloned using the StrataClone Blunt PCR Cloning Kit (Agilent Technologies, USA). Plasmids were purified using GenUP™ Plasmid Kit (biotechrabbit GmbH, Germany) and evaluated by EcoRI restriction digestion (ThermoFisher Scientific). Plasmids bearing inserts with the expected size were sequenced using standard M13 primers by LGC Genomics.

Sequence analyses and alignments
Forward and reverse sequence reads were assembled de novo, edited and translated into their predicted protein sequences using Geneious Prime 2019.2 (Biomatters, Ltd.). A 29-bp intron was deleted prior to the translation of p67 sequences into protein. All p67 sequences were categorised based on the absence/presence of a 43 aa deletion initially described by Nene et al. (1996). The buffalo-derived p67 alleles were further classified into allele types 2, 3 and 4 according to a previously published classification scheme (Sibeko et al. 2010).
For reference, we used four published sequences with Accession Numbers XP_763305, AAB0673, AFU34359 and AFU34364 representing alleles 1-4, respectively (Supplementary Fig. 1). All p67 sequences missing the 43 aa were designated as cattle-derived T. parva strains. All unique sequences were queried against the online GenBank database using the Basic Local Alignment Search Tool (BLAST) for similarity matches with other published sequences. Nucleotide and amino acid sequence alignments were generated using MAFFT V.7 and MUSCLE, respectively, and percent pairwise identity matrices were generated in Geneious Prime 2019.2 software.

Selection analysis in the Tp2 coding sequence
As available evidence shows that long-term immunity induced by ITM is largely mediated by CD8 + T cell responses, we focused our analysis for historical selection on the Tp2 coding sequence. We considered the Tanzania cattle and buffalo Tp2 sequences as one regional T. parva population; hence the Tp2 sequences were grouped into 2 populations (Tanzanian and Kenyan Tp2), and separate codon optimised alignments were created using MUSCLE codon in MEGAx  (Kumar et al. 2018). Due to sequence length differences resulting from quality trimming of the non-cloned cattle sequences, the aligned matrices were truncated to equal lengths of 483 bp spanning the six mapped epitope region to create gapless alignments. The likelihood scores for 88 different nucleotide substitution models were computed for each aligned sequence matrix, and the best-fitting model was selected based on the Akaike information criterion (AIC) using the jModeltest2 program (Darriba et al. 2012). Using the selected model, maximum likelihood (ML) phylogenies were inferred using PAUP version 4 (Swofford 2003), and nonsynonymous to synonymous nucleotide substitution rates were estimated using the CodeML tool of PAML package (Yang 2007) implemented in the EasyCodeML visual selection analysis tool (Gao et al. 2019). Molecular evolution site models (M1a, M2a, M7, M8) were evaluated, and maximum likelihood inferences of positive selection based on AIC to compare model fit (M1a: neutral against M2a: positive selection) and M7 (β) vs. M8 (β and ω) were performed. Positively selected sites were identified based on Bayes empirical Bayes (BEB) posterior probability calculations (Yang et al. 2005).

Results
A total of 160 and 100 cattle samples were processed from northern Tanzania and Central Kenya, respectively. However, we successfully amplified 39 and 36 sequences for the T. parva p67 gene and 33 and 40 sequences for the T. parva Tp2 gene from Tanzania and Kenya, respectively. Out of 22 analysed buffalo samples, only four generated PCR amplicons from which ten unique p67 and six Tp2 cloned sequences were obtained.
Tanzania pastoralist cattle are exposed to buffaloassociated T. parva strains From the 39 T. parva p67 sequences from pastoralist cattle northern Tanzania, we observed a high level of sequence conservation with 85% of these sequences (n = 33) being identical at the nucleotide level and classed as cattle-derived on the basis of the 43 aa deletion in the central region of the gene. BLAST analysis using the 33 sequences as input revealed 100% identity to AVT43014, a p67 allele that was isolated from cattle co-grazing with buffalo in a game conservancy in central Kenya (Sitt et al. 2019). Two other unique p67 sequences also exhibited > 99% identity to AVT43014 at the protein level (Table 1). Interestingly, four animals had p67 sequences that did not contain the 43 aa deletion and were therefore categorised as being of buffalo origin. Further analysis revealed that these four sequences also did not have the additional 174 bp deletion used to distinguish allele 3 from allele type 4. These four sequences translated into two unique amino acid sequences (MT365019 and MT365020) both of which exhibited > 95% identity to the AFU34364 isolated from a South African buffalo (Sibeko et al. 2010).
These findings were comparable to the results of the analysis that we conducted on the samples from the interface area in Kenya. In particular, of the 36 samples typed for p67 allele, 81% (n = 29) were also 100% identical to the cattle type p67 allele, AVT43014, that was isolated from cattle co-grazing with buffalo at the Ol Pejeta Conservancy in central Kenya (Sitt et al. 2019). Similarly, only a minority of the animals typed (n = 7) were classified as being of buffalo origin ( Table 1).
Out of the 22 analysed buffalo samples, only four buffalo samples generated PCR amplicons from which ten unique p67 cloned sequences were obtained comprising allele types 2 and 3 (Table 1).

p67 epitope polymorphisms
Six antibody epitopes have been mapped on the p67 protein, two of which are closely juxtaposed in the central region of the protein (Nene et al. 1999). The first of these two epitopes within the central region (TmM12 epitope) was conserved in all sequences categorised as cattle type (allele 1) or buffalo type (allele 2) except for one sequence from Kenya cattle ( M T 3 6 5 0 0 7 ) w h i c h h a d a s i n g l e s u b s t i t u t i o n (TKEEVPPADLSDQVL) ( Table 2). This amino acid substitution has been observed among cattle type alleles from South Africa in a recent study (Mukolwe et al. 2020). As shown in Table 2, two buffalo p67 type 3 alleles had 7 substitutions in this epitope that have previously been reported in Kenya and South Africa (Sibeko et al. 2010;Sitt et al. 2019), while the remaining buffalo type 3 and 4 alleles had 5 substitutions (Table 2). AR22.7 is the second epitope in the central region (LQPGKTS) and our analysis shows that it was conserved in all cattle type 1 alleles and a single buffalo type 2 allele (MT44097), while all remaining buffalo type 2 alleles in this study had a single substitution (LPPGKTS) when compared with the T. parva Muguga stock. The AR22.7 epitope orthologous sequences in both buffalo types 3 and 4 were identical but were conserved at only three positions LKNGRTD with respect to the T. parva Muguga reference stock (Table 2).

Sequence diversity in the Tp2 candidate vaccine antigen in the interface areas in Tanzania and Kenya samples
Tp2 is a T. parva candidate subunit vaccine antigen containing epitopes recognised by cytotoxic T lymphocytes from immune African cattle (Akoolo et al. 2008). We amplified the gene encoding Tp2 from the 33 African indigenous zebu cattle sampled in northern Tanzania. Collapsing of identical reads revealed a total of 13 unique Tp2 nucleotide sequences from the Tanzanian zebu population, three of which had substitutions that were nonsynonymous at the amino acid level. Two out of the three unique Tp2 sequences have previously been described and one was novel (MT334677). The previously described Tp2 protein sequences were 100% identical to Tp2 variants present within the T. parva Muguga/Serengeti (MT334672) and Kiambu-5 strain variants (MT334671). Percentage pairwise comparisons of the unique Tp2 predicted proteins (Fig. 2) showed a higher level of similarity within Tanzania cattle samples with an average amino acid similarity of 95.10% (± 2.81 SD). Our analysis showed a similar level of polymorphisms in the Tp2 antigen gene in the Marula cattle-buffalo interface area in Kenya. In particular, 9 unique Tp2 nucleotide sequences were identified from the 40 cattle sampled in Kenya. These translated into 5 protein variants (Accession nos. MT334662-MT334666). Two variants (MT334665 and MT334666) were identical to T. parva Muguga/Serengeti and T. parva Kiambu-5 Tp2 antigens, respectively, while one protein variant (MT334663) was identical to a Tp2 variant (AFC18340) in a T. parva isolate that originated from a Kenyan buffalo. Additionally, this latter protein variant (MT334663) was identical to two Tanzania buffalo T. parva Tp2 clones (MT334658 and MT334659) obtained from the current study. Two novel Tp2 protein variants (MT334664 and MT334662) from Kenya are reported in this study. As shown in Fig. 2, percentage pairwise comparisons of these unique Tp2 from Kenya revealed a mean pairwise amino acid identity of 75.46% (±18.28 SD). It is noteworthy that of the 6 Tanzanian buffalos that we typed for Tp2, all the animals carried unique Tp2 nucleotide sequences and only two were synonymous at the amino acid level. The five unique Tanzanian buffalo Tp2 sequences have been deposited in GenBank with accession numbers: MT334656-MT334658 and MT334660-MT334661. As expected, most of the diversity in the Tp2 antigen gene was seen in isolates of buffalo origin, with a mean pairwise percent identity of 70% (Fig. 2).

Novel Tp2 epitope variants
The analysis of the six mapped Tp2 epitopes within the predicted proteins showed sequences obtained from Tanzania cattle to be the most conserved with only two epitopes, Tp 2 27-37 and Tp 2 137-147, being polymorphic. Epitope Tp 2 27-37 had two variants (SHEELKKLGML and SDEELNKLGML), which are closest to Muguga/Serengeti and Kiambu-5, respectively (Fig. 1, Table 3). Epitope Tp 2 137-147 also had two variants (KTSIPNPCKW and KTSVPNPCKW), the latter of which is a novel variant from this study while the former is conserved in the three Muguga cocktail vaccine stocks (Pelle et al., 2011). In contrast, 2-5 epitope variants were identified in all the Kenyan Tp2 epitope sequences, while the Tanzanian buffalo Tp2 sequences had at least 3-5 variants per epitope (Table 3). Further, one novel variant (SGEELNKLGML) within epitope Tp 2 27-37 and two variants (KQKIPNPCDW and KTSIPNPRKW) within epitope Tp 2 137-147 were identified in the buffalo Tp2 sequences (Fig. 3, Table 3).

Discussion
The infection and treatment method of immunisation against T. parva uses stabilates produced from parasites that are   (Table 4) (Yang et al. 2005) transmissible between cattle. The ability of T. parva derived from Cape buffalo to 'break through' the immunity induced by ITM has been documented in multiple studies in Kenya Radley et al. 1979;Sitt et al. 2015). Vaccinated cattle may be susceptible to challenge with parasites from buffalo because the immunity induced by ITM is partially strain-specific, and the diversity of T. parva genotypes is greater in Cape buffalo than in cattle as revealed by genome sequencing (Hayashida et al. 2012), variation within antigen encoding genes (Pelle et al. 2011) and analyses of the variable number of tandem repeats (VNTR) (Oura et al. 2011). There have as yet been no studies of ITM effectiveness, or parasite population genetic diversity in areas where buffalo interface closely with cattle in Tanzania, and the question of genetic similarity between parasite populations in cattle and buffalo has not yet been addressed. Interestingly, in contrast to Kenya, there has not been any observation of 'breakthrough' in ITM-immunised cattle by buffalo-derived parasites in the field in northern Tanzania, where there has been widespread adoption of ITM on a large scale especially among the pastoralist communities in northern Tanzania (Di Giulio et al. 2009). Our present analyses represent an exploration of whether multiple buffalo-derived T. parva genotypes, with variable p67 sequences, are infecting cattle herds located in close proximity with buffalo in northern Tanzania.
Cattle-transmissible T. parva genotypes in East Africa frequently carry type 1 p67 alleles, whereas p67 alleles 2, 3 and 4 represent markers for parasites with a high probability of a recent origin from buffalo (Nene et al. 1996;Obara et al. 2015). The current study establishes that although a majority of the cattle in the northern Tanzania region are infected with cattle-transmissible T. parva genotypes, some of the animals are infected with T. parva genotypes with p67 sequences suggesting a likely recent origin from buffalo. This finding generally conforms to the distribution of p67 alleles at the interface area in Kenya that we evaluated (although the buffalo-derived p67 genotypes were different) and also to the situation reported in previous studies (Mukolwe et al. 2020;Obara et al. 2015;Sitt et al. 2019). It is also important to note that this pattern of p67 allelic polymorphism is consistent with a scenario whereby frequent transmission of parasites from buffalo to cattle occurs, but many fail to permanently establish in cattle following initial infection, because insufficient progression of buffalo-derived parasites to the tickinfective erythrocytic piroplasm stage occurs to enable onward transmission between cattle by ticks (Mbizeni et al. 2013;Morrison et al. 1989). Interestingly, our analysis showed that the cattle in northern Tanzania were infected with buffalo-derived T. parva genotypes classified as type 4 allele on the basis of their p67 sequences. The fact that we did not detect the buffalo-derived allele type 4 of p67in our buffalo samples may have been the result of under sampling; hence, further in-depth sampling will improve the understanding of allele distribution patterns in the region. Previous analyses had suggested that this allele, which has been found in buffalo T. parva in South Africa, seems to be rare within East Africa (Mukolwe et al. 2020;Obara et al. 2015;Sibeko et al. 2010;Sitt et al. 2019). By contrast, buffalo-derived T. parva alleles 2 and 3 genotypes which we found in our Kenyan sample dataset were also reported in previous studies (Obara et al. 2015;Sitt et al. 2019), but not observed in the Tanzanian cattle samples studied.
Recombinant versions of the T. parva p67 major sporozoite surface protein, combined with adjuvants, have been extensively evaluated as anti-sporozoite vaccine candidates. Needle challenges using sporozoite stabilates derived from ground up whole ticks consistently resulted in approximately 70% efficacy against either heterologous or homologous challenge in  (Bishop et al. 2003;Musoke et al. 1992). However, when cattle were exposed to natural tick challenge in the field, the levels of protection observed were only 45% (Musoke et al. 2005). Although the reason for this reduction is not understood, and such field studies are yet to be undertaken in areas where cattle interface with buffalo, p67 polymorphisms in the epitopes recognised by anti-sporozoite monoclonal antibodies are nevertheless worthy of investigation. Our analysis revealed a previously unidentified p67 epitope variant. Contrary to the complete conservation of the p67 locus in cattle-transmissible T. parva isolates that have been studied, we observed an amino acid substitution L 183 within the Kenyan p67 sequence (accession no. MT365007) in the epitope defined by tmM12 ( 169 TKEEVPPADLSDQVP 183 ). This amino acid substitution has been observed in a buffaloderived T. parva type 1 allele from South Africa in a recent study (Mukolwe et al. 2020). However, unlike the single substitution reported in this study, the South African type 1 allele carries two polymorphisms within the TmM12 epitope when compared with the T. parva Muguga reference stock. It is also important to note that long-term immunity against T. parva has been demonstrated to be mediated by CD8+ T cells specific for schizont-infected lymphocytes (McKeever et al. 1994). T. parva genes encoding antigens that are the targets of this protective response in exotic taurine cattle have been identified and named Tp1-Tp8 (Graham et al. 2006), and Tp9-Tp10 . Subsequent studies showed that, with the exception of Tp2, peptides derived from the Tp antigens are not recognised by immune bovine CD8+ T cells from African Zebu (Bos indicus) cattle (Akoolo et al. 2008). We therefore studied variation in the Tp2 epitopes and assessed the evidence for positive selection in the buffaloassociated cattle isolates from northern Tanzania and from the Marula area in central Kenya. Four novel Tp2 epitope variants were found, three of which were identified in the buffalo Tp2 sequences from Tanzania. Interestingly, one of the four variants identified from the Tanzanian cattle sample was within epitope Tp2 137-147 (Table 2), which is an epitope known to be recognised by cytotoxic T lymphocytes (CTL) from African Zebu cattle (Akoolo et al. 2008), which are the predominant breed kept by the Maasai in northern Tanzania. Consistent with previous studies of the molecular evolution of the Tp2 antigen, our analysis did not provide evidence for enrichment of positively selected codons within the mapped Tp2 epitopes (Amzati et al. 2019;Pelle et al. 2011). However, ideally the molecular evolution of the Tp2 and other antigen genes should be addressed without the confounding issue of the potential presence of sequences derived from the ITM vaccine. ITM-vaccinated animals remain carriers of a ticktransmissible infection for up to 14 years ) and ITM genotypes have been detected in unvaccinated cattle. A carrier state of this longevity might result in vaccination contributing to homogenisation of parasite populations.
One major distinction between the cattle sampled in Kenya and those from Tanzania is that the infected Kenyan cattle exhibited a typical buffalo-derived T. parva clinical syndrome characterised by low schizont parasitosis and piroplasm parasitaemia, and many ultimately died . By contrast, the cattle sampled from northern Tanzania were asymptomatic and presumably represented carrier animals that had survived infection. The reasons for this difference in susceptibility are unclear. One possible explanation for this observation is that there is extensive genetic exchange between buffalo-derived and cattle-derived parasites due to long-term buffalo-derived parasite tick challenge of Maasai cattle in Tanzania and that those calves that survive to adulthood are immune to local parasites. Although there is presently insufficient data to confirm this hypothesis, such genetic exchange and alteration of allelic frequencies have been demonstrated experimentally by feeding ticks on cattle co-infected with parasite clones and analysing progeny clones for evidence of recombination (Henson et al. 2012;Katzer et al. 2011).
In conclusion, the evidence of exposure of cattle in northern Tanzania to buffalo-derived T. parva shows the need for further investigations into parasite population genomics and the contribution to induction of immunity in adult cattle as a result of natural challenge by ticks that have fed on buffalo. It will also be important to identify T. parva genes encoding antigens that are recognised by bovine CD8 T cells from immune zebu and buffalo. Additionally, a study using a larger sample size that simultaneously examines the tick and the parasites present in the vector, in wildlife-cattle interface areas where there has been large-scale ITM deployment, should further illuminate the long-term effects of vaccination on T. parva population genomics.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.